Literature DB >> 7044518

Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma.

S E Vogl, M Berenzweig, F Camacho, E Greenwald, B H Kaplan.   

Abstract

Thirty patients with advanced non-small cell bronchogenic carcinoma were treated with cis-platin, 75 mg/M2 weekly for three weeks, then every three weeks. Eighteen were ambulatory, 22 had distant metastases, 14 had prior irradiation, and none had prior chemotherapy. Ten patients (33%) had objective remissions lasting a median of three months. Responders lived a median of five months, compared to three months for nonresponders. Transient mild azotemia was noted in twelve patients. Cis-platin has definite but modest activity in non-small cell bronchogenic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7044518     DOI： 10.1002/1097-0142(19820701)50:1<24::aid-cncr2820500106>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Chemotherapy in non-small cell lung cancer.

Authors:  C J Sweeney; A B Sandler
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.

Authors:  A Veronesi; V Zagonel; M Santarossa; U Tirelli; E Galligioni; M G Trovo'; S Tumolo; E Grigoletto
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.

Authors:  P Drings; U Abel; H Bülzebruck; P Stiefel; M Kleckow; H G Manke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.

Authors:  D R Gandara; E A Perez; H Wold; V Caggiano; M Malec; D K Ahn; F Meyers; R W Carlson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798

Review 7.  Lung cancer in the elderly: current and future chemotherapeutic options.

Authors:  Stuart Hinton; Alan Sandler
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Surgical treatment of brain metastases of lung cancer: retrospective analysis of 89 cases.

Authors:  H Nakagawa; Y Miyawaki; T Fujita; S Kubo; K Tokiyoshi; K Tsuruzono; K Kodama; M Higashiyama; O Doi; T Hayakawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 9.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects.

Authors:  H Nakagawa; T Fujita; S Izumimoto; Y Miyawaki; S Kubo; Y Nakajima; K Tsuruzono; K Kodama; M Higashiyama; O Doi
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.